526. Evaluation of Healthcare Personnel Exposed to Inpatients with Novel Influenza A (H1N1) _ Texas, April - May 2009
Session: Poster Session: Hospital-acquired and Transplant Infections
Friday, October 30, 2009: 12:00 AM
Room: Poster Hall A
Background: A novel influenza A (H1N1) virus with sustained human-to-human transmission emerged in 2009. Healthcare personnel (HCP) can acquire this virus from close contact with infected patients, but no data exist regarding such transmission. We investigated potential transmission to and protective behaviors of HCP in three Texas hospitals with confirmed H1N1 inpatients.
Methods: We surveyed both exposed HCP (identified by each hospital’s infection control program as having come within 6 feet of an H1N1-infected inpatient) and a convenience sample of nonexposed HCP about specific exposures to H1N1-infected patients, influenza-like illness (ILI) 1-7 days after such exposure, use of personal protective equipment (PPE), potential community exposures, and antiviral prophylaxis. Acute and convalescent sera were drawn for serologic testing at CDC.
Results: We interviewed 84/100 exposed HCP and 89/94 nonexposed HCP. The 73 (87%) exposed HCP who took chemoprophylaxis initiated oseltamivir 1-12 days (median, 4 days) after first exposure to an infected patient. Three (3.6%) HCP had ILI after exposure; no nonexposed HCP had recent ILI (Fisher’s exact test P = .12). Of the three HCP with ILI, all had received oseltamivir 4 days after initial exposure; one wore gloves; one wore a surgical mask, gown, and gloves; and one wore an N95 respirator (but had never been fit-tested), gown, gloves, and face shield. Of the 81 exposed HCP without ILI, 45 (56%) wore an N95 respirator; 16 (20%) wore a surgical mask; and 20 (25%) wore neither. Serology results are pending.
Conclusions: Although a substantial number of HCP wore minimal PPE and had delayed postexposure antiviral chemoprophylaxis, few HCP exposed to H1N1-infected inpatients experienced ILI. However, we cannot draw conclusions regarding optimal PPE based on these results; further study is needed.
Tracy Ayers, MS1, Fatimah Dawood, MD1, Lyn Finelli, DrPH, MS2, Vincent Fonseca, MD3, George Han, MD4, Kathy Hancock, PhD1, Alexander Kallen, MD, MPH, FSHEA2, Jacqueline Katz, PhD1, Kai-Wood Ma, MD, MPH5, Manoj Menon, MD, MPH1, Sonja Olsen, PhD1 and  G. S. Han, None..
T. L. Ayers, None..
K. Ma, None..
J. M. Katz, None..
K. Hancock, None..
L. Finelli, None..
M. P. Menon, None..
F. S. Dawood, None..
A. J. Kallen, None..
S. J. Olsen, None..
V. P. Fonseca, None., (1)CDC, Atlanta, GA, (2)Centers for Disease Control and Prevention, Atlanta, GA, (3)Texas Dept. of State Health Services, Austin, TX, (4)CDC, Harrisburg, PA, (5)U.S. Air Force Sch. of Aerospace Med., Brooks City-Base, TX